TYRA
Tyra Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.07
−1.91%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -29.8%
- EBIT
- -31.9%
- EPS
- -34.8%
- Free cash flow
- -26.7%
- Operating cash flow
- -26.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +36.1%
- EPS
- -13.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- -38.9%
- EBIT
- -27.4%
- Net income
- -38.7%
- EPS
- -33.1%
- Free cash flow
- -35.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026